ArticleBMC biology2025
Joint fusion of sequences and structures of drugs and targets for identifying targets based on intra and inter cross-attention mechanisms.
Article in BMC biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Resnet-Driven In Silico Identification of Lead Peptides from the Venom Gland Transcriptome ofPharmaceuticals (Basel, Switzerland) · 2026Article
- Machine Learning for Multi-Target Drug Discovery: Challenges and Opportunities in Systems Pharmacology.Pharmaceutics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundAccurately identifying targets not only guides treatments for diseases with unclear pathogenic mechanisms, but also reduces pharmaceutical costs and accelerates drug development timelines. However, the primary challenge in targets identification currently lies in the low accuracy of existing computational methods.
resultsWe propose MM-IDTarget, a novel deep learning framework that employ a multimodal fusion strategy based on the intra and inter cross-attention mechanisms. MM-IDTarget integrates some cutting-edge deep learning techniques such as graph transformer, multi-scale convolutional neural networks (MCNN), and residual edge-weighted graph convolutional network (EW-GCN) to extract sequence and structure modal features of drugs and targets. This framework enhances the complementary of multimodal features by employing the intra and inter cross-attention mechanisms, facilitating effective fusion of multimodal features within drug and target and between drug and target. Furthermore, MM-IDTarget incorporates the physicochemical features of drug and target, utilizing fully connected networks to predict drug-target interactions (DTI).
conclusionsExperimental results show that despite our benchmark dataset being one-third or the same size of those used by current state-of-the-art methods, MM-IDTarget achieves the performance on par with or superior to these methods across most Top-K evaluation metrics based on the same test set for targets identification. Moreover, MM-IDTarget exhibits the strong application capability on two generalization datasets and one dataset constructed from approved drugs, establishing it as a robust tool for targets identification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.